Business Context and Reporting Period
Company: Sunshine Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2023 (Event Date)
Reporting Period: The filing covers a private placement transaction entered into on May 12, 2023, which closed on May 16, 2023.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics include:
- Gross Proceeds: Approximately $5.0 million received upon closing.
- Securities Issued:
- 2,450,000 shares of Common Stock.
- 3,502,381 Pre-Funded Warrants (exercisable at $0.001).
- Investor Warrants to purchase up to 11,904,762 shares of Common Stock.
- Offering Prices:
- Common Stock + 2 Investor Warrants: $0.84 per unit.
- Pre-Funded Warrant + 2 Investor Warrants: $0.839 per unit.
- Transaction Costs: Placement agent commission of 10% of gross proceeds plus a 2% non-accountable expense allowance.
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of new common stock and warrants. The company has entered into a Material Definitive Agreement (Securities Purchase Agreement) and a Registration Rights Agreement requiring the filing of a resale registration statement within 15 days of closing.
Guidance, Outlook, and Risks
- Management Commentary: The filing confirms the successful closing of the private placement on May 16, 2023.
- Contingencies: The Company is obligated to pay liquidated damages to investors if it fails to file the resale registration statement on time, fails to have it declared effective within the required timeframe (15 days after filing or 45 days if reviewed), or fails to maintain its effectiveness.
- Warrant Terms: Investor Warrants have an exercise price of $0.59 per share and expire five and a half years from issuance.
- Risks: Potential dilution from the exercise of 11.9 million Investor Warrants and 3.5 million Pre-Funded Warrants.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 12% total placement agent fees (10% commission + 2% expense allowance).
- Confirm the filing date and effectiveness status of the resale registration statement required under the Registration Rights Agreement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.2) for specific covenants or restrictions.
- Assess the impact of the 11.9 million Investor Warrants on future share count and potential dilution.